Nevertheless, our PDX cohorts consistently showed tumor growth inhibition and increased sensitivity to combination therapy, supporting the clinical relevance of targeting PRMT1 in HNSCC. Here, PRMT1 is linked to head and neck squamous cell carcinoma.